Abnormal serum phosphate (hypophosphataemia or hyperphosphataemia)
BioMG follows French guidelines. Adapt it to the guidelines and the tests available where you practise.
Hypophosphataemia (< 0.8 mmol/L)
Fasting laboratory tests in the morning
- Serum phosphate (repeat)
- Serum calcium
- Serum albumin
- Serum creatinine with eGFR
- 25-hydroxyvitamin D (reimbursed) (persistent hypophosphataemia: osteomalacia suspected)if neededConfirmed hypophosphataemia without obvious shift cause: hyperparathyroidism secondary to vitamin D deficiency (sun, intake, malabsorption) is one cause [2]. The NABM reimburses 25-hydroxyvitamin D only if rickets or osteomalacia is suspected, among others [3]. Write the indication (suspected osteomalacia) on the prescription; outside this suspicion, the test would be “NR” (not reimbursable in France) [3].
- PTH, on the same sample as the serum calcium (if serum calcium high-normal or raised)if neededHypophosphataemia with high-normal or high serum calcium: consider primary hyperparathyroidism [2] (see the Hypercalcaemia page). The NABM limits PTH to the diagnosis of parathyroid adenoma, among others [3]. Here, the question asked is indeed the diagnosis of a parathyroid adenoma: PTH reimbursed, without “NR” (not reimbursable in France) [3].
If persistent hypophosphataemia with no obvious cause (TmP/GFR)
- The same fasting morning: serum phosphateif needednon-French guidelineUnexplained chronic hypophosphataemia: TmP/GFR (maximum tubular reabsorption of phosphate relative to GFR) looks for renal phosphate wasting; it is calculated on the 2nd morning fasting void, collected at the same time as the blood [2].
- Serum creatinineif needednon-French guidelineUnexplained chronic hypophosphataemia: TmP/GFR (maximum tubular reabsorption of phosphate relative to GFR) looks for renal phosphate wasting; it is calculated on the 2nd morning fasting void, collected at the same time as the blood [2].
- And on the 2nd morning voiding: urinary phosphateif needednon-French guidelineUnexplained chronic hypophosphataemia: TmP/GFR (maximum tubular reabsorption of phosphate relative to GFR) looks for renal phosphate wasting; it is calculated on the 2nd morning fasting void, collected at the same time as the blood [2].
- Urinary creatinine (TmP/GFR calculation)if needednon-French guidelineUnexplained chronic hypophosphataemia: TmP/GFR (maximum tubular reabsorption of phosphate relative to GFR) looks for renal phosphate wasting; it is calculated on the 2nd morning fasting void, collected at the same time as the blood [2].
Do not order
- Phosphate reabsorption calculated on 24-hour urine: depends on dietary intake and ignores variations in serum phosphate during the day; prefer TmP/GFR on a morning sample [2].
Hyperphosphataemia (> 1.45 mmol/L)
Fasting laboratory tests in the morning
- Serum phosphate (repeat, on a non-haemolysed sample)
- Serum creatinine with eGFR
- Serum calcium
- Serum albumin
- Serum protein electrophoresis (if unexplained hyperphosphataemia with normal renal function)if needednon-French guidelineHyperphosphataemia without renal failure or obvious cause: a monoclonal immunoglobulin (myeloma) can distort the colorimetric phosphate assay (pseudohyperphosphataemia); in a case review, almost all hyperphosphataemias reported in myeloma were artefacts [9].
- Serum magnesium (if serum calcium low)if neededHyperphosphataemia with low serum calcium and normal renal function (possible hypoparathyroidism): hypomagnesaemia is a curable cause of functional hypoparathyroidism (PPIs in particular) [10].
- PTH, on the same sample as the serum calcium (if low serum calcium with normal renal function)if neededHypocalcaemia with hyperphosphataemia and normal renal function: a low or inappropriate PTH makes the diagnosis of hypoparathyroidism [10]. Outside thyroidectomy and dialysis, PTH falls outside the NABM indications: “NR” (not reimbursable in France) [3]. See the “Hypocalcaemia” page.
- PTH, reimbursed (after thyroidectomy, or dialysis patient)if neededAfter thyroidectomy (diagnosis and follow-up of hypoparathyroidism) or in dialysed patients, PTH falls within the NABM indications of code 0983: do not write “NR” (not reimbursable in France); in other situations, use the previous line [3].
Sources (12)
- Bex S, Mollard F, Stirnemann J. Que faire de l'hypophosphatémie ? Rev Med Suisse. 2019;15:1871-5.
- Aljuraibah F, Bacchetta J, Brandi ML, et al. An expert perspective on phosphate dysregulation with a focus on chronic hypophosphatemia. J Bone Miner Res. 2022;37(1):12-20.
- Assurance maladie. Nomenclature des actes de biologie médicale (NABM), version 105 : actes 1139 (25-OH-vitamine D) et 0983 (parathormone).
- National Institute for Health and Care Excellence. Nutrition support for adults: oral nutrition support, enteral tube feeding and parenteral nutrition. Clinical guideline CG32, 2006, mise à jour 2017 : recommandation 1.4.6 (encadré 1).
- ANSM, Base de données publique des médicaments. Résumé des caractéristiques du produit FERINJECT 50 mg Fer/mL (carboxymaltose ferrique), rubriques 4.4 et 4.8, et notice, consulté le 11 octobre 2026.
- Agence européenne des médicaments. Viread (ténofovir disoproxil) : résumé des caractéristiques du produit (information produit EPAR), rubrique 4.4, consulté le 11 octobre 2026.
- Medicines and Healthcare products Regulatory Agency (Royaume-Uni). Ferric carboxymaltose (Ferinject▼): risk of symptomatic hypophosphataemia leading to osteomalacia and fractures. Drug Safety Update, 16 novembre 2020 (note complémentaire de septembre 2026).
- US Food and Drug Administration, American Regent. INJECTAFER (ferric carboxymaltose injection), prescribing information, boxed warning « Symptomatic hypophosphatemia » (08/2026), notice DailyMed du 19 août 2026.
- Dabir M, Mousavi MK, Mohamadi M, Maleki A. Pseudohyperphosphatemia in multiple myeloma: a systematic review of case reports and case series. J Clin Lab Anal. 2026;40(15):e70281.
- Haute Autorité de santé, Centre de référence des maladies rares du métabolisme du calcium et du phosphate. Protocole national de diagnostic et de soins (PNDS) : Hypoparathyroïdie. Mars 2025.
- National Institute for Health and Care Excellence. Chronic kidney disease: assessment and management. NICE guideline NG203, 25 août 2021 (dernière mise à jour 24 novembre 2021) : recommandations sur le métabolisme osseux.
- Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2017;7(1):1-59.